Intermittent Intravenous Insulin Therapy

This policy addresses intermittent intravenous (including intraperitoneal) insulin therapy for glycemic control in diabetic patients, primarily discussed for insulin‑dependent (type 1) diabetes. The therapy is considered experimental, investigational and unproven for all indications and is nationally non‑covered for outpatient use (including Medicare NCD 40.7); inpatient IV insulin for acute conditions (e.g., DKA/HHS) is excluded from this policy, any delivery device must be FDA 510(k)-cleared for intravenous medications, and coverage is subject to the member’s benefit plan.

"No covered indications — intermittent intravenous insulin therapy is considered experimental, investigational and/or unproven for all indications."

Sign up to see full coverage criteria, indications, and limitations.